Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 17, 2020

Primary Completion Date

September 15, 2022

Study Completion Date

August 12, 2024

Conditions

Malignant Central Nervous System NeoplasmPrimary Central Nervous System Neoplasm

Interventions

BEHAVIORAL

Cogstate Assessment Battery

Complete CogState testing

DRUG

Memantine

Given PO

DRUG

Memantine Hydrochloride

Given PO

Trial Locations (1)

Mayo Clinic in Rochester, Rochester